Stocktoria
Organogenesis Holdings Inc. ORGO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-12-02
Organogenesis Holdings Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M | $467.4M |
| Gross profit | — | $366.3M | $326.7M | $345.9M | $353.2M |
| R&D expense | $44.5M | $50.3M | $44.4M | $39.8M | $30.7M |
| SG&A expense | $326.2M | $294.5M | $269.8M | $283.8M | $250.2M |
| Operating income | $44.7M | -$1.3M | $12.5M | $22.3M | $72.2M |
| Interest expense | — | — | $2.2M | $2.0M | $7.2M |
| Income tax | $9.9M | -$3.7M | $5.4M | $4.8M | -$31.1M |
| Net income | $37.0M | $861,000 | $4.9M | $15.5M | $94.2M |
| EPS (diluted) | $0.15 | $-0.01 | $0.04 | $0.12 | $0.70 |
| Operating cash flow | -$10.3M | $14.2M | $30.9M | $24.9M | $62.0M |
| Free cash flow | -$24.5M | $4.2M | $6.6M | -$9.0M | $30.8M |
| Cash & equivalents | $93.7M | $135.6M | $103.8M | $102.5M | $113.9M |
| Inventory | $29.6M | $26.2M | $28.3M | $24.8M | $25.0M |
| Total assets | $598.7M | $497.9M | $460.0M | $449.4M | $443.3M |
| Total liabilities | $164.8M | $112.6M | $181.4M | $183.7M | $201.9M |
| Shareholders' equity | $300.1M | $262.9M | $278.7M | $265.7M | $241.3M |
Source: SEC EDGAR filings · CIK 0001661181 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.